What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Immune system
The scientist’s investigation covers issues in Immunology, Transplantation, Internal medicine, T cell and Antigen.
His biological study spans a wide range of topics, including Melanoma, Stem cell and DNA sequencing.
His research investigates the connection between Transplantation and topics such as Leukemia that intersect with issues in Bone marrow, Myeloid leukemia, Chemotherapy and Monoclonal antibody therapy.
His biological study deals with issues like Oncology, which deal with fields such as Allogeneic transplantation and Metastasis.
Karl S. Peggs usually deals with T cell and limits it to topics linked to CD8 and Interferon.
His studies deal with areas such as Cancer research, Virology, Tumor microenvironment, Molecular biology and Transduction as well as Antigen.
His most cited work include:
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade (1503 citations)
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. (911 citations)
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution (604 citations)
What are the main themes of his work throughout his whole career to date?
Karl S. Peggs mainly focuses on Immunology, Transplantation, Internal medicine, Hematopoietic stem cell transplantation and Alemtuzumab.
T cell, Immune system, Immunotherapy, Antigen and CD8 are among the areas of Immunology where the researcher is concentrating his efforts.
His Transplantation study combines topics from a wide range of disciplines, such as Stem cell and Lymphoma.
His Internal medicine research integrates issues from Gastroenterology, Surgery and Oncology.
His Hematopoietic stem cell transplantation research is multidisciplinary, incorporating perspectives in Transplantation Conditioning, Donor Lymphocytes and Intensive care medicine.
His Alemtuzumab research is multidisciplinary, relying on both Fludarabine and Cohort.
He most often published in these fields:
- Immunology (54.17%)
- Transplantation (53.79%)
- Internal medicine (43.56%)
What were the highlights of his more recent work (between 2018-2021)?
- Cancer research (10.61%)
- Transplantation (53.79%)
- Internal medicine (43.56%)
In recent papers he was focusing on the following fields of study:
Karl S. Peggs focuses on Cancer research, Transplantation, Internal medicine, Oncology and Immunology.
His studies in Transplantation integrate themes in fields like Congenital cytomegalovirus infection, Clinical trial and Stem cell.
His research ties Gastroenterology and Internal medicine together.
The various areas that Karl S. Peggs examines in his Oncology study include T cell, Mantle cell lymphoma and Rituximab.
His Immunology study frequently draws connections between adjacent fields such as Lung cancer.
Karl S. Peggs has researched Alemtuzumab in several fields, including Hematopoietic stem cell transplantation, Immunosuppression and Adoptive cell transfer.
Between 2018 and 2021, his most popular works were:
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells (508 citations)
- Neoantigen-directed immune escape in lung cancer evolution (232 citations)
- In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: A systematic literature review (29 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Immune system
Karl S. Peggs mostly deals with Transplantation, Cancer research, Internal medicine, Hematopoietic stem cell transplantation and Immunity.
The Cancer research study combines topics in areas such as Relapsed refractory, B cell and CD19.
His research links Oncology with Internal medicine.
Karl S. Peggs combines subjects such as Gastroenterology, Vitamin D and neurology, Salvage therapy and Intensive care medicine with his study of Hematopoietic stem cell transplantation.
His Immunity study results in a more complete grasp of Immunology.
His Clinical trial research is multidisciplinary, incorporating elements of T cell and Chimeric Antigen Receptor T-Cell Therapy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
